MBX Biosciences, Inc.

In celebration of STEM Day, we’re proud to highlight MBX Biosciences’ commitment to inspiring the next generation of innovators!    Through our ongoing #STEM initiatives, we’re dedicated to sparking curiosity in science, technology, engineering, and math—investing in the leaders of tomorrow who will drive the future of healthcare and patient care.    Join us in celebrating #STEMDay and the role STEM education plays in shaping a future of innovation and impact!     #FutureLeaders #STEMCareers #STEMDay2024

Today, we shared our inaugural #earnings release following our recent #IPO. View our Q3 highlights and upcoming milestones in the press release: https://lnkd.in/e6dNmQn8

Tomorrow, our Scientific Co-Founder, Richard DiMarchi, Ph.D., will be a keystone speaker at the 2024 BioCrossroads Life Sciences Summit in Indianapolis, where he will share insights around the latest innovations shaping #diabetes and #obesity care.    Our Senior Vice President, Discovery & Non-Clinical Development, Michael A. Dorato, PhD, DABT, Fellow ATS, FRSB will also be joining Ruth Gimeno, Ph.D., and Karen Wurster, MBA, for a panel discussion moderated by Dr. Janel Gordon, MD, DipABOM, DipABLM, exploring next generation approaches to diabetes and obesity management.    Don’t miss this opportunity to learn more about recent breakthroughs and forward-looking insights surrounding these #metabolic conditions. Register for the event here: https://bit.ly/3zPzRPA

Our Chief Medical Officer, Salomon (Sam) Azoulay, M.D., attended the HypoPARAthyroidism Association’s International HypoPARAthyroidism Conference this past weekend to share an overview of the Company and MBX-2109, our potential long-acting parathyroid hormone (PTH) peptide prodrug for the treatment of #hypoparathyroidism.   Check out photos from the conference where we shared how we’re working to redefine patient outcomes and enhance the quality of life for hypoparathyroidism patients everywhere.   #endocrine

Our Chief Medical Officer, Salomon (Sam) Azoulay, M.D., attended the HypoPARAthyroidism Association’s International HypoPARAthyroidism Conference this past weekend to share an overview of the Company and MBX-2109, our potential long-acting parathyroid hormone (PTH) peptide prodrug for the treatment of #hypoparathyroidism.   Check out photos from the conference where we shared how we’re working to redefine patient outcomes and enhance the quality of life for hypoparathyroidism patients everywhere.   #endocrine

Last week, we held a company-wide virtual meeting with Patty Keating, Executive Director, and Michele Rayes, Associate Director, of the HypoPARAthyroidism Association. Patty and Michele shared invaluable insights into the daily realities of living with #hypoparathyroidism. Their perspectives underscored the importance of our work and deepened our commitment to making a difference for patients impacted by this challenging condition. At MBX, our mission is to help people with #endocrine and #metabolic disorders live fuller and healthier lives.        Learn more about MBX and explore opportunities to join us in pursuit of this mission by visiting our LinkedIn Careers page: https://bit.ly/3C8NcDc 

The MBX team is participating in three investor conferences this November, including the Guggenheim Inaugural Healthcare Innovation Conference, the Stifel Healthcare Conference and the Jefferies London Healthcare Conference. View full details below and access the live webcasts and replays on our IR site. https://lnkd.in/ebwYDuWq #JefferiesHealthcare

This week, we presented the rationale and design of the Phase 2 Avail™ trial of MBX 2109, our potential long-acting parathyroid hormone (PTH) peptide prodrug, in adults with #hypoparathyroidism (HP) at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting.   Engineered by our proprietary Precision Endocrine Peptide™(PEP™) technology, MBX 2109 is designed to help patients with hypoparathyroidism achieve continuous and consistent PTH exposure to improve total health outcomes and reduce dosing frequency.   We look forward to future developments in our pipeline of PEPs as we continue to push the boundaries of innovation to help people with #endocrine and #metabolic disorders live fuller and healthier lives. Read the full release here: https://lnkd.in/efuK2zVF   #ASBMR2024

Thank you Nasdaq for hosting us this morning to ring the Opening Bell! We appreciate everyone who made it possible for us to share this incredible honor with our friends, employees and partners both virtually and in person.

We are proud to announce that the first patient has been dosed in our Phase 2 AvailTM trial evaluating MBX 2109, our parathyroid hormone (PTH) peptide prodrug that is designed to be long-acting and is in development for the treatment of chronic #hypoparathyroidism (HP). Leveraging our proprietary Precision Endocrine PeptideTM (PEPTM) platform technology, MBX 2109 is designed to provide convenient, once-weekly administration and a continuous, infusion-like PTH exposure with lower daily peak-to-trough ratios than observed with daily PTH dosing regimens. With this milestone, we move forward in our mission to support those with #endocrine disorders in leading fuller and healthier lives. Learn more:https://lnkd.in/e3GJxF2w